Tagged with Boehringer Ingelheim

AMR June 9th 2020 saw the launch of a new action fund on antimicrobial resistance (AMR), with 23 leading biopharmaceutical companies committing to almost USD one billion in investment to save collapsing antibiotic pipelines. The partnership aims to bring between two and four new antibiotics to patients by 2030 and facilitate…

Sweden Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European Union all belie a legacy as a real titan of life sciences.* The country that has introduced some of the most impactful healthcare inventions of the 20th century…

Hungary Francesco Banchi, general manager of Boehringer Ingelheim Hungary, elaborates on the successful development of the affiliate in recent years, making progress in new product reimbursement. As an experienced leader in sales and marketing, Banchi offers his insights into the challenging market access landscape of Hungary and his strategies in cooperating…

Pharma Faces 2019 saw Boehringer Ingelheim (BI) veteran Felix Gutsche take up his first country manager role – of a top-three affiliate, no less – after blazing a rather unorthodox path. From an International Trainee role at BI HQ, he moved into finance, where he stayed for a decade, with stints in…

Sweden Though far from the largest pharma market in Europe, Sweden nevertheless holds strategic importance for global pharma; from the country’s attitude to public health to its sophisticated digital framework, comprehensive patient registries and innovative spirit. Here, four pharma country managers hailing from outside Sweden’s borders give their first impressions of…

China Boehringer Ingelheim veteran executive Felix Gutsche shares the first impressions of the China market since he joined in January 2019; the strategic significance of the market as one of the top three affiliates for the Group globally across both Human Pharma and Animal Health business units; his mission to better…

Thailand Thailand is becoming an increasingly attractive location for pharma companies to conduct clinical trials, with multinationals such as Novo Nordisk and Boehringer Ingelheim conducting more and more of their global trials in the country.   We are very active in engaging Thai doctors and patients in benefiting from involvement in…

Thailand Diabetes affects more than eight percent of the Thai population, a number that is on the rise, and nearly half of these cases remain undiagnosed. In light of this epidemic, local diabetes associations and multinational pharma companies based in Thailand are coming together to provide awareness, education, and support to…

Thailand Dr Armin Wiesler, general manager and head of Human Pharma at Boehringer Ingelheim (Thai) Ltd., explores how the affiliate has managed to achieve market-leading growth rates and addressed the challenges and opportunities inherent in the Thai pharma market for Boehringer Ingelheim.   The pharma industry in Thailand is very dynamic…

Sweden Andrea Sambatti is the general manager of Boehringer Ingelheim (BI) Sweden and is a member of the board of directors for LIF. Sambatti discusses how Sweden is a testbed for innovation and often one of the first places where pharma companies launch their products. She also discusses how Sweden is…

Spain Against an alluring backdrop, big-name pharma brands are now starting to spend heavily on in-country manufacturing, development and shared service facilities in Spain.   Spain has exceedingly high youth unemployment. However, the country simultaneously possesses some of the best business universities, technical schools and hospitals. This means that it is…

Spain With Spain now on the road to economic recovery following the ravages of the global financial crisis, multinational pharmaceutical companies are seeing the country as a top investment destination once more thanks to a much-improved market access scenario, high-quality but affordable manufacturing capabilities and an enviable human resource base. As…